Respiratory Medicine
Volume 104, Issue 8 , Pages 1092-1100 , August 2010

The use of non-routine pleural fluid analysis in the diagnosis of pleural effusion

Received 3 September 2009 ,Accepted 15 March 2010.

References 

  1. Porcel JM. Tuberculous pleural effusion. Lung. 2009;
  2. Baba K, Sornes S, Hoosen AA, Lekabe JM, Mpe MJ, Langeland N, et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect Dis. 2008;8:35
  3. Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med. 2008;102(5):744–754[4]
  4. Lee YC, Rogers JT, Rodriguez RM, Miller KD, Light RW. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. 2001;120(2):356–361
  5. Porcel JM, Vives M. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. 2002;121(4):1379–1380
  6. Jimenez Castro D, Diaz Nuevo G, Perez-Rodriguez E, Light RW. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. Eur Respir J. 2003;21(2):220–224
  7. Light RW. Pleural diseases. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 211–24
  8. Pérez-Rodriguez E, Light RW. Effusions from infections: tuberculosis. In:  Light RW,  Gary Lee YC editor. Textbook of pleural diseases. 2nd ed.. London: Hodder Arnold; 2008;p. 367–378
  9. Zemlin AE, Burgess LJ, Carstens ME. The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis. 2009;13(2):214–220
  10. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58(Suppl. 2):ii8–ii17
  11. Staats BA, Ellefson RD, Budahn LL, Dines DE, Prakash UB, Offord K. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc. 1980;55(11):700–704
  12. Hamm H, Brohan U, Bohmer R, Missmahl HP. Cholesterol in pleural effusions. A diagnostic aid. Chest. 1987;92(2):296–302
  13. Yilmaz A, Tunaboyu IK, Akkaya E, Bayramgurler B. A comparative analysis of the biochemical parameters used to distinguish between pleural exudates and transudates. Respirology. 2000;5(4):363–367
  14. Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of interferon-gamma in tuberculous pleurisy: a meta-analysis. Chest. 2007;131(4):1133–1141
  15. Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis. 2003;7(8):777–786
  16. Villena V, Lopez-Encuentra A, Pozo F, Echave-Sustaeta J, Ortuno-de-Solo B, Estenoz-Alfaro J, et al. Interferon gamma levels in pleural fluid for the diagnosis of tuberculosis. Am J Med. 2003;115(5):365–370
  17. Hooper CE, Lee YC, Maskell NA. Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope?. Curr Opin Pulm Med. 2009;15(4):358–365
  18. Ariga H, Kawabe Y, Nagai H, Kurashima A, Masuda K, Matsui H, et al. Diagnosis of active tuberculous serositis by antigen-specific interferon-gamma response of cavity fluid cells. Clin Infect Dis. 2007;45(12):1559–1567
  19. Losi M, Bossink A, Codecasa L, Jafari C, Ernst M, Thijsen S, et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J. 2007;30(6):1173–1179
  20. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest. 1993;104(5):1486–1489
  21. Bartter T, Santarelli R, Akers SM, Pratter MR. The evaluation of pleural effusion. Chest. 1994;106(4):1209–1214
  22. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003;4(2):72–80
  23. Liao H, Na MJ, Dikensoy O, Lane KB, Randal B, Light RW. Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases. Respirology. 2008;13(1):53–57
  24. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167
  25. Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Gunluoglu MZ, Demir A, et al. The importance of pleural fluid and serum NT-proBNP levels in differentiating pleural effusion due to heart failure from other causes of effusion. Intern Med. 2009;48(5):287–293
  26. Kolditz M, Halank M, Schiemanck CS, Schmeisser A, Hoffken G. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J. 2006;28(1):144–150
  27. Porcel JM, Martinez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest. 2009 Sep;136(3):671–677
  28. Roth BJ, O'Meara TF, Cragun WH. The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest. 1990;98(3):546–549
  29. Han CH, Choi JE, Chung JH. Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions. Intern Med. 2008;47(19):1669–1674
  30. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vila S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86(8):1488–1495
  31. Bielsa S, Esquerda A, Salud A, Montes A, Arellano E, Rodriguez-Panadero F, et al. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Eur J Intern Med. 2009;20(4):383–386
  32. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075–1082
  33. Tomita M, Shimizu T, Matsuzaki Y, Hara M, Ayabe T, Onitsuka T. Prognostic significance of carcinoembryonic antigen level in pleural lavage fluid for patients with lung adenocarcinoma. Ann Thorac Surg. 2005;80(1):276–281
  34. Galbis Caravajal JM, Benlloch Carrion S, Sanchez Paya J, Mafe Madueno JJ, Baschwitz Gomez B, Rodriguez Paniagua JM. Prognostic value of the carcinoembryonic antigen found in pleural lavage fluid from patients with lung carcinoma. Arch Bronconeumol. 2005;41(4):185–188
  35. Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269
  36. Ghayumi SM, Mehrabi S, Doroudchi M, Ghaderi A. Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res. 2005;11(4):236–241
  37. Wagner IC, Guimaraes MJ, da Silva LK, de Melo FM, Muniz MT. Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion. J Bras Pneumol. 2007;33(2):185–191
  38. Li CS, Cheng BC, Ge W, Gao JF. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract. 2007;61(3):444–448
  39. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136–140
  40. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003 Nov 15;362(9396):1612–1616
  41. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006 May 15;173(10):1155–1160
  42. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007 Jul;62(7):569–576
  43. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603
  44. Light RW. Tumor markers in undiagnosed pleural effusions. Chest. 2004;126(6):1721–1722
  45. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126(6):1757–1763
  46. Sahn SA. State of the art. The pleura. Am Rev Respir Dis. 1988;138(1):184–234[54]
  47. Villena V, Perez V, Pozo F, Lopez-Encuentra A, Echave-Sustaeta J, Arenas J, et al. Amylase levels in pleural effusions: a consecutive unselected series of 841 patients. Chest. 2002;121(2):470–474
  48. Foresti V, Villa A, Zubani R. Amylase concentrations in pleural effusions. Chest. 1994;105(5):1625–1626
  49. Ende N. Studies of amylase activity in pleural effusions and ascites. Cancer. 1960;13:283–287
  50. Branca P, Rodriguez RM, Rogers JT, Ayo DS, Moyers JP, Light RW. Routine measurement of pleural fluid amylase is not indicated. Arch Intern Med. 2001;161(2):228–232
  51. Sherr HP, Light RW, Merson MH, Wolf RO, Taylor LL, Hendrix TR. Origin of pleural fluid amylase in esophageal rupture. Ann Intern Med. 1972;76(6):985–986
  52. Kramer MR, Saldana MJ, Cepero RJ, Pitchenik AE. High amylase levels in neoplasm-related pleural effusion. Ann Intern Med. 1989;110(7):567–569
  53. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140–1144
  54. Hara N, Abe M, Inuzuka S, Kawarada Y, Shigematsu N. Pleural SC5b-9 in differential diagnosis of tuberculous, malignant, and other effusions. Chest. 1992;102(4):1060–1064
  55. Halla JT, Schrohenloher RE, Volanakis JE. Immune complexes and other laboratory features of pleural effusions: a comparison of rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Ann Intern Med. 1980;92(6):748–752
  56. Salomaa ER, Viander M, Saaresranta T, Terho EO. Complement components and their activation products in pleural fluid. Chest. 1998;114(3):723–730
  57. Hidaka K, Abe M, Tanaka T, Mitsuyama T, Hara N, Hara N. Comparison of complement activation between tuberculous and malignant pleuritis. Nihon Kyobu Shikkan Gakkai Zasshi. 1995;33(4):379–383
  58. Porcel JM, Vives M, Gazquez I, Vicente de Vera MC, Perez B, Rubio M. Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions. Int J Tuberc Lung Dis. 2000;4(1):76–82
  59. Shitrit D, Ollech JE, Ollech A, Peled N, Amital A, Fox B, et al. Diagnostic value of complement components in pleural fluid: report of 135 cases. Respir Med. 2008;102(11):1631–1635
  60. Joseph J, Sahn SA. Connective tissue diseases and the pleura. Chest. 1993;104(1):262–270
  61. Porcel JM, Ordi-Ros J, Esquerda A, Vives M, Madronero AB, Bielsa S, et al. Antinuclear antibody testing in pleural fluid for the diagnosis of lupus pleuritis. Lupus. 2007;16(1):25–27
  62. Wang DY, Yang PC, Yu WL, Kuo SH, Hsu NY. Serial antinuclear antibodies titre in pleural and pericardial fluid. Eur Respir J. 2000;15(6):1106–1110
  63. Faurschou P. Decreased glucose in RA-cell-positive pleural effusion: correlation of pleural glucose, lactic dehydrogenase and protein concentration to the presence of RA-cells. Eur J Respir Dis. 1984;65(4):272–277
  64. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35(6):368–378
  65. Berkman N, Liss H, Kramer MR. Pyelonephritis as a cause of pleural effusion. Respiration. 1996;63(6):384–386
  66. Falguera M, Lopez A, Nogues A, Porcel JM, Rubio-Caballero M. Evaluation of the polymerase chain reaction method for detection of Streptococcus pneumoniae DNA in pleural fluid samples. Chest. 2002;122(6):2212–2216
  67. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis. 2004;4:6
  68. Ilonidis G, Parapanisiou E, Anogeianaki A, Giavazis I, Theofilogiannakos EK, Tsekoura P, et al. Interleukin-1beta (IL-1 beta), interleukin 6 (IL-6) and tumor necrosis factor (TNF) in plasma and pleural fluid of pneumonia, lung cancer and tuberculous pleuritis. J Biol Regul Homeost Agents. 2006;20(1–2):41–46
  69. Alexandrakis MG, Kyriakou D, Alexandraki R, Pappa KA, Antonakis N, Bouros D. Pleural interleukin-1 beta in differentiating transudates and exudates: comparative analysis with other biochemical parameters. Respiration. 2002;69(3):201–206
  70. Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A, et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med. 2007;101(5):910–918
  71. Xirouchaki N, Tzanakis N, Bouros D, Kyriakou D, Karkavitsas N, Alexandrakis M, et al. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest. 2002;121(3):815–820
  72. Lin FC, Chen YC, Chen FJ, Chang SC. Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions. Clin Immunol. 2005;116(2):166–173
  73. Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, et al. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond). 2003;105(5):601–607
  74. Porcel JM, Galindo C, Esquerda A, Trujillano J, Ruiz-Gonzalez A, Falguera M, et al. Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions. Respirology. 2008;13(1):58–62
  75. Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-González A, Martínez-Iribarren A, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J. 2009 Dec;34(6):1383–1389
  76. Porcel JM, Ruiz-Gonzalez A, Falguera M, Nogues A, Galindo C, Carratala J, et al. Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. Chest. 2007;131(5):1442–1447
  77. Budak F, Uzaslan EK, Cangur S, Goral G, Oral HB. Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines. Lung. 2008;186(5):337–343
  78. Vavetsi R, Bonovas S, Polizou P, Papanastasopoulou C, Dougekou G, Sitaras NM. The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study. BMC Pulm Med. 2009;9:9
  79. Soderblom T, Pettersson T, Nyberg P, Teppo AM, Linko L, Riska H. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J. 1999;13(3):519–522

PII: S0954-6111(10)00125-3

doi: 10.1016/j.rmed.2010.03.008

Respiratory Medicine
Volume 104, Issue 8 , Pages 1092-1100 , August 2010

Article Tools